ArticleBMJ open2026
Therapeutic use of cold-stored platelets in humans: protocol for a systematic review and meta-analysis.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionInterest in cold-stored platelets (CSP) has seen a resurgence over the last 20 years, having not been clinically used since the 1980s. A multitude of in vitro studies have reported positive characteristics such as improved haemostatic function and longer storage duration in CSP compared with their room-temperature-stored counterparts. More recently, CSP have been investigated in clinical trials and used to improve supply chain resilience in some settings. This systematic review and meta-analysis will synthesise and describe the published evidence on the therapeutic use of CSP to determine the feasibility, safety and efficacy of their use and identify key areas for future research. METHODS AND ANALYSIS: The Medline, Cochrane and EMBASE databases will be searched from inception to date of search for all studies including therapeutic transfusions of CSP in the English language as well as grey literature searches. Abstract screening and shortlisted full-text screening will be performed by two independent reviewers, adjudicated by a third reviewer. The data will be extracted by two reviewers and a narrative review formulated. Risk of bias will be assessed using the risk-of-bias tool for randomised trials (RoB-2) and the Risk of Bias In Non-randomized Studies - of Interventions tool. A meta-analysis will be undertaken using fixed-effect or random-effects models, contingent on the degree of statistical heterogeneity, as quantified by the I² statistic. ETHICS AND DISSEMINATION: No ethical review is required as no original data will be collected. Results will be disseminated through peer-reviewed publication and at academic conferences. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD420251086610.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.